	Bénéfice Avant Impôts		Date
AbbVie	USD 4.38B	1.92B	2025-09
Agios Pharmaceuticals	USD -109.06M	5.62M	2025-12
ALKERMES	USD 100.74M	4.1M	2025-09
Alnylam Pharmaceuticals	USD 161.14M	77.83M	2025-12
Amgen	USD 3.92B	2.35B	2025-09
Biogen	USD 557.3M	186.7M	2025-09
BioMarin Pharmaceutical	USD -26.32M	324.19M	2025-09
Bristol-Myers Squibb	USD 3.11B	1.34B	2025-09
Coherus Biosciences	USD -47.4M	14.9M	2025-03
Eli Lilly	USD 7.23B	456M	2025-09
Gilead Sciences	USD 3.64B	1.21B	2025-09
GlaxoSmithKline	GBP 1.23B	1.23B	2025-12
Glaxosmithkline	GBP 2.46B	569M	2025-09
Incyte	USD 389.94M	92.37M	2025-12
J&J	USD 4.97B	2.53B	2025-12
Merck	USD 6.74B	22M	2025-09
Moderna	USD -187M	631M	2025-09
Neurocrine Biosciences	USD 239.4M	52.4M	2025-12
Novartis	USD 4.2B	335M	2025-09
Pfizer	USD 3.33B	290M	2025-09
PTC Therapeutics	USD -139.08M	116.01M	2025-12
Puma Biotechnology	USD 20.61M	24.76M	2024-09
Regeneron Pharmaceuticals	USD 1.76B	244.6M	2025-09
Sangamo BioSciences	USD -36.05M	12.94M	2024-06
Sanofi	EUR -1.16B	5.5B	2025-12
Sarepta Therapeutics	USD -407.67M	213.63M	2025-12
United Therapeutics	USD 444M	6M	2025-12
Vertex Pharmaceuticals	USD 1.3B	15.8M	2025-09

Gilead Sciences Bénéfice Avant Impôts - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - Feb 2026.